Literature DB >> 17899204

Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker.

Claudio Celentano1, Federico Prefumo, Elena di Vera, Annamaria Iannicco, Davide Pio Gallo, Marco Liberati.   

Abstract

We report on a case of fetal toxicity due to maternal treatment with olmesartan medoxomil. At 29 weeks' gestation, oligohydramnios was found, although the fetus had normal kidneys on ultrasound evaluation. Withdrawal of olmesartan medoxomil, maternal rehydration, and a single dose of furosemide reversed the renal impairment. After term delivery, the neonate was confirmed to have normal renal function. The case suggested that fetal renal impairment due to olmesartan medoxomil may be reversible.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17899204     DOI： 10.1007/s00467-007-0618-8

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


  12 in total

1.  Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists.

Authors:  Farida Daïkha-Dahmane; Evelyne Levy-Beff; Myriam Jugie; Richard Lenclen
Journal:  Pediatr Nephrol       Date:  2006-03-25       Impact factor: 3.714

Review 2.  Angiotensin II receptor antagonist treatment during pregnancy.

Authors:  S Alwan; J E Polifka; J M Friedman
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2005-02

3.  Losartan and fetal toxic effects.

Authors:  H Saji; M Yamanaka; A Hagiwara; R Ijiri
Journal:  Lancet       Date:  2001-02-03       Impact factor: 79.321

4.  Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a medicaid managed care organization.

Authors:  Catherine E Cooke; Hugh Fatodu
Journal:  J Manag Care Pharm       Date:  2006-10

Review 5.  Clinical pharmacology of furosemide in children: a supplement.

Authors:  J Prandota
Journal:  Am J Ther       Date:  2001 Jul-Aug       Impact factor: 2.688

6.  Defining the susceptible period of developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats.

Authors:  S G Spence; H L Allen; M A Cukierski; J M Manson; R T Robertson; R S Eydelloth
Journal:  Teratology       Date:  1995-06

7.  Hemodynamic and fluid responses to furosemide infusion in the ovine fetus.

Authors:  T F Kelly; T R Moore; R A Brace
Journal:  Am J Obstet Gynecol       Date:  1993-01       Impact factor: 8.661

Review 8.  Teratogen update: angiotensin-converting enzyme inhibitors.

Authors:  M Barr
Journal:  Teratology       Date:  1994-12

9.  Acute maternal hydration in third-trimester oligohydramnios: effects on amniotic fluid volume, uteroplacental perfusion, and fetal blood flow and urine output.

Authors:  N J Flack; W Sepulveda; S Bower; N M Fisk
Journal:  Am J Obstet Gynecol       Date:  1995-10       Impact factor: 8.661

10.  Angiotensin-converting enzyme inhibitor fetopathy.

Authors:  P G Pryde; A B Sedman; C E Nugent; M Barr
Journal:  J Am Soc Nephrol       Date:  1993-03       Impact factor: 10.121
View more
  4 in total

1.  Postnatal acute renal failure after fetal exposure to angiotensin receptor blockers.

Authors:  Luca Marchetto; Desiree Sordino; Giuseppe De Bernardo; Daniele Trevisanuto
Journal:  BMJ Case Rep       Date:  2015-07-02

Review 2.  Outcomes of 83 fetuses exposed to angiotensin receptor blockers during the second or third trimesters: a literature review.

Authors:  Chisa Shimada; Rina Akaishi; Kazutoshi Cho; Mamoru Morikawa; Yosuke Kaneshi; Takahiro Yamda; Hisanori Minakami
Journal:  Hypertens Res       Date:  2015-02-19       Impact factor: 3.872

3.  Olmesartan medoxomil-induced acute renal failure in a premature newborn following maternal exposure during pregnancy: a case report and review of the literature.

Authors:  Eleni Georgaki-Angelaki; Nicolaos Stergiou; Ekaterini Naoum; Ioannis Papassotiriou; Marina Anagnostakou
Journal:  NDT Plus       Date:  2009-04-22

4.  Reversible Fetal Renal Impairment following Angiotensin Receptor Blocking Treatment during Third Trimester of Pregnancy: Case Report and Review of the Literature.

Authors:  Tal Saar; Lorinne Levitt; Hagai Amsalem
Journal:  Case Rep Obstet Gynecol       Date:  2016-09-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.